Skip to main content
. 2020 May 21;7(6):ofaa184. doi: 10.1093/ofid/ofaa184

Table 2.

Empiric and Definitive Intravenous Therapy

Empiric Therapy Definitive Therapy
Period 1 (n = 371) Period 2 (n = 87) Period 3 (n = 121) Period 1 (n = 371) Period 2 (n = 87) Period 3 (n = 121)
Vancomycin, No. (%) 331 (89) 75 (86) 94 (78) 143 (39) 38 (44) 29 (24)
Daptomycin, No. (%) 16 (4.3) 1 (1.1) 10 (8.3) 19 (5.1) 4 (4.6) 8 (6.6)
Oxacillin, No. (%) 2 (0.54) 0 (0) 0 (0) 50 (13) 4 (4.6) 26 (21)
Cefazolin, No. (%) 1 (0.27) 2 (2.3) 0 (0) 127 (34) 34 (39) 45 (37)
Other,a No. (%) 17 (4.6) 7 (8.0) 17 (14) 23 (6.2) 5 (5.7) 13 (11)
None, No. (%) 4 (1.1) 2 (2.3) 0 (0) 9 (2.4) 2 (2.3) 0 (0)

aOther agents included cefepime, ceftriaxone, clindamycin, doxycycline, ertapenem, levofloxacin, linezolid, meropenem, piperacillin/tazobactam, and telavancin.